← Back to Search

Virus Therapy

poly ICLC for Ovarian Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

Study Summary

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Poly ICLC may stop the growth of liver cancer by blocking blood flow to the tumor. Giving the drug directly into the arteries around the tumor may kill more tumor cells. Giving cyclophosphamide and radiation therapy together with poly ICLC may be an effective treatment for liver cancer. PURPOSE: This phase I/II trial is studying the side effects of giving cyclophosphamide, radiation therapy, and poly ICLC together and to see how well they work in treating patients with unresectable, recurrent, primary, or metastatic liver cancer.

Eligible Conditions
  • Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Liver Cancer
  • Skin Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall tolerability
Secondary outcome measures
Overall survival at 6, 12, and 24 months
Progression-free survival at 6, 12, and 24 months

Trial Design

1Treatment groups
Experimental Treatment
Group I: poly ICLCExperimental Treatment4 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
poly ICLC
2003
Completed Phase 2
~190
hepatic artery embolization
2014
Completed Phase 3
~160
3-dimensional conformal radiation therapy
2007
Completed Phase 3
~2690

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
429 Previous Clinical Trials
64,218 Total Patients Enrolled
5 Trials studying Ovarian Cancer
373 Patients Enrolled for Ovarian Cancer
Andrew N. de la Torre, MDStudy ChairUMDNJ University Hospital / St Joseph Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025